Fundamental Data for MTOX

Medtox Scientific sells laboratory testing services in forensic toxicology, clinical toxicology, & heavy metal analyses as well as from mfd. products including a variety of on-site screening products. The Company''s customers for abused substance testing include public and private corporations. Among this customer base are Fortune 500 companies. In addition to public and private corporations, abused substance testing is also conducted on behalf of service firms such as financial institutions, drug treatment counseling centers and hospitals.

# Employees: 523

Address: 402 West County Road D,St. Paul,MN,USA

Phone: 651 636-7466

Fax: 651 636-5351

Website: www.medtox.com

Email: investors@MEDTOX.com

Sector: Medical

Industry: MED-OUTP/HM CRE

Executive Officers

Richard J. Braun (Chmn.; Presi; C.E.O.)

Kevin J. Wiersma (V.P.; C.F.O.)

Steven J. Schmidt (V.P.; Fin.)

Robert J. Marzec (Dir.)

Samuel C. Powell (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/10/2010

Mean EPS (Next Qtr): $0.08

Mean EPS (Year): $0.25

Mean Estimate(Long Term): $22.00

P/E Ratio(Based on EPS estimate): 36.000

Number of Estimates: 1

Shares Performance

Period	MTOX	Compare to S&P
YTD	9.49 %	-9.39 %
4 Weeks	-9.82 %	-14.39 %
12 Weeks	-0.55 %	-7.39 %

Shares Information

Analyst Coverage: Y

Avg Volume: 26718

Shares Outstanding: 8M

Market Cap: $0.08B

52 Week High: $10.17

52 Week Low: $5.95

P/E Ratio: 39.130

PEG Ratio: 1.640

Split: On 8/23/2004 MTOX split by factor of 1.500

Earnings Performance

EPS Growth in Last Quarter: 125.00 %

EPS Growth in Last Year: -52.63 %

Sales Growth in Last Quarter: 4.35 %

Sales Growth in Last Quarter: -0.66 %

Financials

Qtr Book Value: $1.25

Cash Flow/Share: $7.32

Change in Payout Ratio: 0.000

Price/Sales: 0.900